Executive Summary & Comparative Analysis

The global Flavors and Fragrances (F&F) industry represents a compelling, non-cyclical sector with defensive growth characteristics, underpinned by its integral role in the global consumer staples value chain. The industry’s products are essential components in a vast array of end markets, including food and beverages, personal care, and household goods, providing a resilient demand profile even during periods of economic uncertainty. The market was valued at approximately USD 29.1 billion in 2022 and is projected to expand at a compound annual growth rate (CAGR) of 5.4% to reach USD 44.5 billion by 2030, driven by long-term secular trends.¹

Key investment themes shaping the sector include:

1. Defensive Consumer Staples Exposure: The non-discretionary nature of the end products provides a stable and predictable revenue base.
2. Secular Growth Drivers: Growth is propelled by rising disposable incomes in emerging markets, which fuel demand for processed foods and consumer goods, and the powerful consumer-led shift toward health, wellness, and natural or “clean-label” products in mature markets.²
3. Oligopolistic Industry Structure: The market is highly concentrated among four dominant players—Givaudan, International Flavors & Fragrances (IFF), dsm-firmenich, and Symrise. This structure creates significant barriers to entry, stemming from immense scale, proprietary R&D and intellectual property, deep integration into customer product development cycles, and extensive regulatory expertise. This affords the incumbents significant and durable pricing power.

However, the period between 2022 and 2024 has been marked by significant headwinds. The industry has navigated unprecedented raw material cost inflation, persistent global supply chain disruptions, and geopolitical tensions affecting sourcing and logistics.⁴ Concurrently, the competitive landscape has been reshaped by transformative M&A activity, most notably the merger of DSM and Firmenich and the ongoing, complex integration of DuPont’s Nutrition & Biosciences (N&B) division by IFF, which has introduced significant execution risk and balance sheet pressure for the involved parties.

The following dashboard provides a high-level quantitative comparison of the key publicly listed companies analyzed in this report, offering an initial framework for understanding their relative scale, profitability, and market valuation.

Table 1: Key Company Metrics – Comparative Dashboard

Company	Ticker	Market Cap (USD Bn)	LTM Revenue (USD Bn)	LTM EBITDA Margin (%)	LTM Net Debt/EBITDA	LTM ROIC (%)	EV/LTM EBITDA	LTM P/E
Large-Cap Leaders
Givaudan SA	GIVN.SW	41.5	7.9	23.8%	2.4x	N/A	21.1x	36.4x
International Flavors & Fragrances Inc.	IFF	19.4	11.4	19.1%	3.8x	1.0%	13.7x	(23.4x)
dsm-firmenich AG	DSFIR.AS	28.2	13.8	16.5%	1.3x	N/A	12.8x	23.8x
Symrise AG	SY1.DE	15.6	5.4	20.7%	2.3x	8.7%	15.6x	22.9x
Mid-Cap & Diversified Players
Sensient Technologies Corp.	SXT	4.7	1.5	16.5%	2.1x	N/A	14.9x	35.9x
Kerry Group plc	KRZ.L	16.0	8.6	15.7%	2.1x	10.6%	14.6x	22.0x
Corbion NV	CRBN.AS	1.3	1.4	13.6%	2.1x	N/A	10.1x	16.4x
Archer Daniels Midland Co. (Nutrition)	ADM	25.9	7.3	5.3%	N/A	N/A	N/A	19.4x
Smaller Specialists
Robertet SA	RBT.PA	1.7	0.9	19.4%	N/A	11.9%	12.3x	20.5x
Takasago International Corp.	4914.T	0.9	1.5	7.2%	N/A	N/A	10.4x	16.6x
Note: Data as of latest available reporting periods. Market data is approximate and subject to change. Some metrics (e.g., ROIC, Net Debt/EBITDA) may not be available or directly comparable for all companies due to reporting differences. ADM metrics are for the Nutrition segment where applicable; Market Cap and P/E are for the consolidated company.

Global Flavor & Fragrances Industry Outlook

Market Dynamics & Growth Drivers

The F&F industry is characterized by stable, mid-single-digit growth, with the global market projected to expand at a 5.4% CAGR from 2023 to 2030.¹ The flavors segment, which constitutes the larger portion of the market at 56.19% in 2024, is forecast to grow at a slightly faster 5.65% CAGR.² This growth is supported by several powerful and enduring secular trends.

The Dominant Shift to Natural Ingredients: The most significant driver reshaping the industry is the persistent consumer demand for natural, organic, and “clean-label” products. The global natural F&F market is growing at a premium to the overall market, with a projected CAGR of 6.3%.⁶ This trend is not marginal; natural ingredients constituted approximately 74.25% of the total market revenue in 2022.¹ This demand is forcing consumer packaged goods (CPG) companies to reformulate products with natural and plant-based ingredients, creating a substantial tailwind for F&F suppliers who can provide these solutions.² Essential oils are a dominant product category within the naturals segment, accounting for over 74% of revenue in 2021.⁶

Growth in High-Value Adjacent Markets: The F&F industry is a critical enabler for growth in adjacent consumer markets. The proliferation of plant-based and alternative protein products, for instance, relies heavily on sophisticated flavor and texturizing solutions to mask off-notes and replicate traditional sensory experiences. Similarly, the functional beverage market, which includes drinks with added vitamins, minerals, and botanicals, is fueling demand for innovative flavor profiles that can deliver health benefits without compromising on taste.⁷

Emerging Market Consumption Patterns: The long-term growth algorithm for the F&F industry is heavily weighted toward emerging economies. Rising urbanization and increasing disposable incomes in regions like Asia-Pacific and Latin America are driving a dietary shift towards more processed and packaged foods, convenience meals, and beverages.² This structural shift directly expands the addressable market for F&F ingredients. Asia-Pacific stands out as both the largest market, commanding 31.68% of 2024 revenue, and the fastest-growing region, with a projected CAGR of 5.61% through 2030.³

Technological Innovation as a Differentiator: The industry is leveraging technological advancements to meet evolving consumer demands. Innovations in encapsulation and delivery systems allow for time-released fragrances in laundry detergents or flavor protection during food processing. Furthermore, leading producers are increasingly using artificial intelligence and data analytics to identify regional taste preferences and accelerate the creation of customized flavor profiles, enhancing their value proposition to customers.²

Industry Structure & Competitive Landscape

The F&F industry is a classic oligopoly, with the top four players—Givaudan, dsm-firmenich, IFF, and Symrise—controlling a substantial majority of the global market. This consolidated structure creates formidable and durable barriers to entry, which are the foundation of the industry’s attractive economics and pricing power.

Key Barriers to Entry:

• Scale and Global Reach: The largest players benefit from significant economies of scale in manufacturing, procurement of raw materials, and distribution. Their global footprint allows them to serve large multinational CPG clients seamlessly across all major markets.
• Research & Development and Intellectual Property: The industry is knowledge-intensive. Leading firms invest heavily in R&D, typically 7-10% of sales, to maintain vast libraries of proprietary flavor and fragrance compounds, patented molecules, and innovative technologies. This intellectual property is nearly impossible for new entrants to replicate.
• High Customer Switching Costs: F&F suppliers are not mere commodity providers; they are deeply integrated partners in their customers’ product development processes. A specific flavor or fragrance is often a core part of a consumer product’s identity and brand equity. Changing a key ingredient requires extensive reformulation, consumer testing, and regulatory approvals, creating significant switching costs and fostering long-term, sticky customer relationships.
• Regulatory Complexity: The industry operates within a stringent and complex global regulatory framework governing food safety, chemical usage, and labeling. Navigating these regulations requires substantial expertise and resources. For example, the International Fragrance Association’s (IFRA) 51st Amendment introduced 48 new ingredient restrictions, necessitating extensive reformulation and supply chain adjustments across the industry, a hurdle that disproportionately favors established players with dedicated regulatory departments.³

This market structure leads to a competitive dynamic based primarily on innovation, quality, service, and regulatory assurance, rather than on price alone.

A critical dynamic shaping the industry is the “natural premium” paradox. The clear and accelerating consumer shift toward natural ingredients is a primary growth engine. However, it simultaneously introduces significant operational and financial complexity. Natural raw materials are subject to far greater price and supply volatility due to their dependence on agricultural yields, climate conditions, and the geopolitical stability of their sourcing regions.⁹ This volatility directly pressures gross margins and complicates supply chain management. Consequently, the ability to profitably and reliably supply natural ingredients at scale has become a key competitive differentiator. Companies that have secured their supply chains through vertical integration, long-term grower contracts, or advanced sourcing technologies are better positioned to navigate this challenge. This trend is not merely a sales tailwind but a fundamental test of operational excellence that is likely to widen the performance gap between the industry leaders and their smaller rivals.

Despite the powerful trend toward naturals, synthetic ingredients remain foundational to the industry. They accounted for over 66% of the flavors market in 2024 and nearly 70% of the overall F&F market, primarily due to their significant advantages in cost-effectiveness, stability, and scalability.³ For mass-market consumer goods where cost-in-use is paramount, synthetics are often the only viable option. Moreover, certain scent profiles and functional ingredients cannot be sustainably sourced or replicated from natural origins at an industrial scale. This reality necessitates a dual-pronged strategy for the major players: maintaining a cutting-edge, high-margin naturals portfolio for premium applications while also operating a highly efficient, scaled synthetics business for the mass market. This bifurcation underscores the comprehensive capabilities required for market leadership.

Company Profiles: Large-Cap Leaders

A. Givaudan SA (GIVN.SW)

1. Business Model & Market Position

Givaudan is the global leader in the F&F industry, operating through two well-balanced divisions: Taste & Wellbeing (flavors and food ingredients) and Fragrance & Beauty (fragrances, active beauty ingredients).10 The company has a strategically diversified geographic footprint, with 37% of 2022 sales from Europe, Africa, and the Middle East (EAME), 26% from North America, 25% from Asia Pacific, and 12% from Latin America. This includes a significant and balanced exposure to both high-growth markets (54% of sales) and mature markets (46% of sales), providing a blend of stability and growth potential. Givaudan holds a particularly strong, market-leading position in the high-margin Fine Fragrances category, which serves the world’s leading luxury and designer perfume brands.10

2. Competitive Advantages & Differentiation

Givaudan’s primary competitive advantage lies in its unwavering commitment to innovation, backed by the industry’s highest R&D investment as a percentage of sales. In 2022, the company invested CHF 522 million, or 7.3% of sales, into research and development. This investment fuels a powerful innovation engine, protected by a portfolio of over 4,000 active patents. The company’s business model is centered on a deep, collaborative co-creation process with its customers, leveraging its 65 creation and application centers worldwide to develop bespoke, value-added solutions. This deep integration makes Givaudan a critical partner, not just a supplier, creating exceptionally high switching costs for its clients. The company also operates its own Perfumery and Flavourist schools, ensuring a pipeline of world-class creative talent.10

3. Financial Performance Analysis

Givaudan has a long track record of consistent and profitable growth. For the full year 2023, the company reported sales of CHF 6.9 billion, representing like-for-like (LFL) growth of 4.1%. It demonstrated strong pricing power, successfully implementing price increases to fully compensate for higher input costs.12 The company’s profitability is robust, with a 2023 EBITDA margin of 21.3% and a comparable EBITDA margin of 22.4%.12 This performance was even stronger in 2024, with full-year sales reaching CHF 7.4 billion (+12.3% LFL) and an EBITDA margin of 23.8%.11 Givaudan is also a strong generator of cash flow, achieving a record free cash flow (FCF) of CHF 920 million in 2023, representing an impressive 13.3% of sales.12 The company has consistently increased its dividend since its IPO in 2000, proposing a dividend of CHF 68.00 per share for 2023 and CHF 70.00 for 2024.11

4. Recent Developments & Industry Headwinds (2022-2024)

Throughout the inflationary period of 2022-2023, Givaudan demonstrated superior operational execution and pricing power, successfully passing on rising raw material and energy costs to its customers. The company continued its disciplined strategy of bolt-on acquisitions to augment its capabilities, particularly in naturals and active beauty ingredients. Its 2025 strategy, “Committed to Growth, with Purpose,” remains on track, with ambitious financial targets of 4-5% average LFL sales growth and >12% FCF as a percentage of sales, which it is on pace to meet or exceed.14 The company has shown resilience in a challenging macroeconomic environment, with strong performance in high-growth markets and Fine Fragrances offsetting softness in other areas.12

5. Valuation Analysis

Givaudan consistently trades at a significant premium to its industry peers, a reflection of its perceived quality, consistent execution, and strong financial returns. As of mid-2024, its trailing twelve-month (TTM) price-to-earnings (P/E) ratio stood at approximately 36x.16 This valuation is well above its historical averages and those of its direct competitors. The premium is supported by its best-in-class profitability, strong and predictable cash flow generation, and a track record of disciplined capital allocation that has created substantial long-term shareholder value.

6. Risk Assessment

The primary risk associated with Givaudan is its premium valuation. The current multiples leave little room for operational missteps. Any slowdown in growth, margin compression, or failure to meet its 2025 targets could trigger a significant de-rating of the stock. Its strong position in Fine Fragrances, while a source of high margins, also exposes the company to shifts in discretionary consumer spending on luxury goods. Finally, as the undisputed market leader, maintaining its edge and finding new avenues for outsized growth becomes incrementally more challenging.

7. Investment Thesis Considerations

• Bull Case: The bull case rests on the argument that Givaudan is the “best-in-class” operator in a highly attractive, defensive industry. Its premium valuation is justified by its superior and consistent financial performance, innovation leadership, and disciplined execution of its long-term strategy. The company is well-positioned to continue capitalizing on secular growth trends in health, wellness, and naturals, delivering predictable, compounding returns for shareholders.
• Bear Case: The bear case centers on valuation risk. The stock is priced for perfection, and any deviation from its historical growth and profitability trajectory could lead to substantial downside. The law of large numbers may also begin to constrain its ability to grow faster than the underlying market, making it difficult to sustain its premium multiple over the long term.

B. International Flavors & Fragrances Inc. (IFF)

1. Business Model & Market Position

Following its transformative merger with DuPont’s Nutrition & Biosciences (N&B) division in 2021, IFF became the industry’s largest company by revenue. It operates across four distinct segments: Nourish (food ingredients, flavors, savory solutions), Health & Biosciences (probiotics, cultures, enzymes, home and personal care ingredients), Scent (fragrance compounds and ingredients), and Pharma Solutions (pharmaceutical excipients).18 This structure gives IFF an unparalleled product breadth, spanning the full spectrum from traditional flavors and fragrances to highly specialized, science-backed functional ingredients.

2. Competitive Advantages & Differentiation

IFF’s primary competitive advantage is its unmatched scale and the sheer breadth of its product portfolio. The N&B merger endowed it with world-leading positions in high-value specialty ingredients such as probiotics, cultures, and enzymes, areas where its traditional F&F peers have less of a presence. This allows IFF to offer integrated solutions to customers that combine taste, texture, health, and preservation, a unique and compelling value proposition.

3. Financial Performance Analysis

The period following the N&B merger has been challenging. While the merger dramatically increased IFF’s revenue base, with reported net sales of $11.48 billion in 2024, top-line growth has been stagnant, and profitability has been severely impacted by integration costs and writedowns.19 The company reported a GAAP net loss of $2.57 billion in 2023 and $835 million in the trailing twelve months (TTM) ending Q1 2025, driven by significant goodwill impairment charges.20 To assess the underlying business health, it is crucial to analyze comparable, currency-neutral results. On this basis, sales grew 6% in 2024, led by strong performance in Scent and Health & Biosciences.19 However, the company’s balance sheet is heavily leveraged, with net debt to credit-adjusted EBITDA standing at 3.8x at the end of 2024, a key concern for investors.19

4. Recent Developments & Industry Headwinds (2022-2024)

IFF’s recent history is dominated by its strategic transformation and efforts to manage the complexities of the N&B integration. In early 2025, the company announced a significant restructuring, separating its Nourish segment into two new divisions, Taste and Food Ingredients.21 This move was accompanied by a massive non-cash goodwill impairment charge of $1.15 billion related to the legacy N&B Food & Beverage assets, signaling that the initial valuation and synergy assumptions of the merger were overly optimistic.21 In response to its high debt load, management has initiated a significant portfolio optimization program, aiming to divest non-core assets. A key step in this process is the planned divestiture of the Pharma Solutions business.19 The company has also seen significant management changes, including the appointment of a new CEO, J. Erik Fyrwald, in early 2024, tasked with steering the turnaround.23

5. Valuation Analysis

Reflecting the significant operational and financial challenges, IFF trades at a steep discount to its high-quality peers. The company’s TTM P/E ratio is negative due to GAAP losses, and its forward P/E and EV/EBITDA multiples are substantially lower than those of Givaudan and Symrise.24 The market valuation clearly incorporates a high degree of execution risk and uncertainty regarding the timing and success of the company’s turnaround strategy and deleveraging efforts.

6. Risk Assessment

The risk profile for IFF is elevated. The foremost risk is execution risk related to the ongoing integration and strategic transformation. The ability to successfully separate and divest assets, capture remaining synergies, and streamline the organization remains a significant challenge. The high leverage is a major concern, making the company more vulnerable to economic downturns or interest rate fluctuations. There is also a risk of further asset impairments if the performance of the acquired N&B businesses does not improve as anticipated.

7. Investment Thesis Considerations

• Bull Case: The bull case is a classic turnaround story. The market is seen as excessively penalizing IFF for its post-merger difficulties. The underlying portfolio of assets, particularly in Health & Biosciences and Scent, is world-class. If the new management team can successfully execute the divestiture program to pay down debt and streamline operations, there is significant potential for margin expansion and a substantial re-rating of the stock from its current depressed valuation.
• Bear Case: The bear case posits that the N&B merger was a strategic misstep from which the company may struggle to recover. The sheer complexity of the integration has overwhelmed the organization, as evidenced by the massive writedowns. The promised synergies may never fully materialize, leaving IFF as a high-debt, low-growth, and inefficiently managed conglomerate that will continue to underperform its more focused peers.

C. dsm-firmenich AG (DSFIR.AS)

1. Business Model & Market Position

dsm-firmenich was formed in May 2023 through the merger of Dutch nutrition and materials science company Royal DSM and Swiss private F&F house Firmenich, creating a new industry powerhouse.26 The company is structured into four business units: Perfumery & Beauty, Taste, Texture & Health, Health, Nutrition & Care, and Animal Nutrition & Health. This combination creates a unique profile, blending Firmenich’s creative expertise in F&F with DSM’s scientific and biotech capabilities in vitamins, enzymes, and nutritional ingredients. As part of its strategic repositioning, the company is in the process of separating and divesting its Animal Nutrition & Health business to focus on the higher-margin consumer-facing segments.28

2. Competitive Advantages & Differentiation

The core competitive advantage of dsm-firmenich is its uniquely comprehensive and science-backed portfolio. It is the only major player that combines top-tier capabilities in perfumery and taste with a deep, scientific foundation in health and nutrition. This allows the company to offer integrated solutions that address multiple consumer trends simultaneously—for example, creating a great-tasting, plant-based food product that is also fortified with specific vitamins and probiotics. This holistic “Health, Nutrition & Beauty” positioning is a key differentiator.

3. Financial Performance Analysis

As a newly merged entity, the financial track record is short, with analysis focusing on pro-forma results and recent performance. For the first half of 2025, dsm-firmenich reported strong results, with group sales of €6.5 billion, reflecting 7% organic growth, and an adjusted EBITDA of €1.26 billion.29 The adjusted EBITDA margin improved significantly to 19.4% from 15.5% in the prior-year period, driven by good organic growth and the realization of merger synergies.29 The company is on track to achieve its target of approximately €350 million in total Adjusted EBITDA from synergies.30

4. Recent Developments & Industry Headwinds (2022-2024)

The company’s entire recent history is defined by the merger and subsequent integration and portfolio reshaping. A key strategic priority is the separation and exit of the Animal Nutrition & Health segment, which will transform the company into a pure-play consumer-focused entity. To this end, it completed the sale of its Feed Enzymes business for €1.5 billion in June 2025.31 The company is also actively returning capital to shareholders, having initiated a €1 billion share buyback program in April 2025.31 Management is focused on delivering on its ambitious cost and revenue synergy targets, which are a critical component of the investment case.

5. Valuation Analysis

The market is still establishing a clear valuation framework for the combined entity. Based on forward estimates, the company trades at a P/E ratio of approximately 21-24x.32 A sum-of-the-parts analysis, considering the distinct valuations of its different business segments, is a relevant approach. The valuation will be highly sensitive to the company’s ability to deliver on its synergy targets and successfully execute the divestiture of the Animal Nutrition & Health business at an attractive price.

6. Risk Assessment

Similar to IFF, dsm-firmenich faces significant integration risk. The merger combined two large organizations with distinct national and corporate cultures (Dutch and Swiss), which can create unforeseen challenges. The simultaneous execution of a large-scale integration and a major business carve-out is a complex undertaking that places significant demands on management. Failure to deliver on the promised €350 million in synergies would likely lead to a negative re-evaluation by the market.

7. Investment Thesis Considerations

• Bull Case: The merger of DSM and Firmenich has created a new, uniquely positioned leader in the attractive Health, Nutrition & Beauty space. The combination of scientific prowess and creative artistry provides a durable competitive advantage. If management successfully executes the integration, delivers on synergy targets, and completes the strategic portfolio reshape, the company’s pro-forma earnings power and growth profile could make the current valuation appear attractive.
• Bear Case: The complexity of merging two distinct cultures while simultaneously divesting a major segment is underestimated. The ambitious synergy targets may prove difficult to achieve, and potential disruptions from the complex corporate actions could lead to a period of underperformance relative to more stable, focused peers like Givaudan and Symrise.

D. Symrise AG (SY1.DE)

1. Business Model & Market Position

Symrise is a leading global F&F supplier with a well-balanced portfolio across its two segments: Scent & Care and Taste, Nutrition & Health.34 The company serves a global client base of over 6,000 customers with a portfolio of more than 35,000 products.34 A key element of Symrise’s strategy is its focus on backward integration to secure the supply of key natural raw materials and its expansion into adjacent, high-growth areas beyond traditional F&F, such as pet food and probiotics.34

2. Competitive Advantages & Differentiation

Symrise’s competitive strengths include its strong and diversified portfolio, a robust R&D engine that fosters cross-divisional collaboration, and a proactive approach to supply chain management. Its commitment to backward integration, particularly for strategic natural ingredients like vanilla from Madagascar, provides a crucial advantage in managing the cost and supply volatility that challenges the industry. This strategy not only enhances supply security but also offers greater transparency and sustainability, which is increasingly valued by customers.

3. Financial Performance Analysis

Symrise has a strong and consistent track record of delivering profitable growth. In fiscal year 2024, the company achieved sales of nearly €5.0 billion, representing strong organic growth of 8.7%.34 Profitability is also a key strength, with the EBITDA margin reaching 20.7% in 2024.36 The company has consistently grown its dividend for 15 consecutive years, proposing a dividend of €1.20 per share for 2024.34 For 2025, while moderating its organic growth outlook to 3-5% in response to a more challenging macroeconomic environment, Symrise increased its profitability target, now expecting an EBITDA margin of approximately 21.5%.37

4. Recent Developments & Industry Headwinds (2022-2024)

In response to the inflationary environment and to enhance operational efficiency, Symrise has implemented its “ONE SYM Transformation” program. This initiative is focused on optimizing the portfolio, driving profitable growth, and improving efficiency. The program is already yielding results, with identified recurring cost savings of €40 million targeted for 2025, half of which was already realized in the first half of the year.37 The company has also been active with bolt-on acquisitions to strengthen its portfolio, particularly in the high-growth pet food and food ingredients spaces.

5. Valuation Analysis

Symrise typically trades at a valuation that is at a slight discount to Givaudan but at a notable premium to IFF. Its TTM P/E ratio is in the range of 23-27x.39 This valuation reflects the market’s appreciation for its consistent operational performance, strong management team, and clear strategic direction. The company is viewed as a high-quality, reliable compounder in the sector.

6. Risk Assessment

Key risks for Symrise include its exposure to raw material price volatility, although its backward integration strategy helps mitigate this. The Scent & Care segment has some exposure to discretionary consumer spending, which could be impacted during economic downturns. Additionally, like its peers, the company faces the ongoing challenge of successfully integrating its bolt-on acquisitions to realize expected synergies and returns.

7. Investment Thesis Considerations

• Bull Case: Symrise represents a high-quality, well-managed company that consistently delivers on its strategic and financial objectives. It offers a compelling combination of defensive growth and operational excellence. For investors seeking exposure to the attractive F&F industry, Symrise provides a slightly more attractively valued alternative to Givaudan, with clear catalysts for margin expansion from its ongoing efficiency programs.
• Bear Case: The company’s moderated growth outlook for 2025 indicates that it is not entirely immune to global macroeconomic headwinds. As its larger competitors IFF and dsm-firmenich complete their respective integrations, Symrise could face heightened competitive pressure. While a high-quality operator, its valuation already reflects much of its positive attributes, potentially limiting the scope for significant multiple expansion.

Company Profiles: Mid-Cap & Diversified Players

A. Sensient Technologies Corporation (SXT)

Sensient is a global manufacturer of colors, flavors, and other specialty ingredients.⁴¹ The company operates through three segments: Flavors & Extracts, Color, and Asia Pacific.⁴² Unlike the large-cap leaders, Sensient has a more focused portfolio, with a particularly strong global position in food, pharmaceutical, and personal care colors. Its competitive advantage lies in its specialized technology, deep customer collaboration, and robust global supply chain.⁴² Financially, Sensient reported revenue of $1.46 billion in 2023.⁴² Recent performance has been solid, with Q2 2025 revenue increasing 2.7% to $414.2 million and reported operating income growing 16.2%.⁴³ The company’s valuation, with a P/E ratio around 35x, reflects its specialized market position and consistent profitability.⁴⁴ Key risks include its dependence on certain raw materials and competition from both large, diversified players and smaller niche specialists.

B. Kerry Group plc (KRZ.L)

Kerry Group is a global taste and nutrition company with deep roots in the Irish dairy industry.⁴⁶ While it has a Dairy Ireland segment, the primary value driver and focus of the company is its Taste & Nutrition business, which provides a vast range of flavor, ingredient, and functional solutions to the food, beverage, and pharmaceutical industries.⁴⁶ The company’s competitive advantage stems from its extensive R&D capabilities (over 1,200 scientists), a broad technology portfolio, and deeply embedded innovation partnerships with customers.⁴⁸ In 2024, Kerry Group generated revenue of €8.0 billion and an EBITDA margin of 15.7%.⁴⁸ The company is executing a portfolio transformation to become a pure-play taste and nutrition company, as evidenced by the recent sale of its sweet ingredients portfolio and a majority of its Dairy Ireland business.⁴⁸ The valuation, with a P/E ratio of approximately 22x, reflects its strong market position and growth prospects, balanced by its more diversified and historically lower-margin profile compared to pure-play F&F leaders.⁴⁹ Risks include managing its complex portfolio and exposure to the volatility of its dairy-related businesses.

C. Corbion NV (CRBN.AS)

Corbion is a Dutch company specializing in bio-ingredient solutions, with a market-leading position in lactic acid and its derivatives.⁵⁰ The company operates through two main business units: Functional Ingredients and Solutions (focused on food preservation and functional systems) and Health and Nutrition (targeting high-growth areas like algae ingredients and medical biopolymers).⁵¹ Its core competency is in fermentation technology, which it uses to create sustainable solutions for food preservation, health, and bioplastics.⁵⁰ In 2024, Corbion generated sales of €1.29 billion with an adjusted EBITDA of €175.0 million.⁵² The company has been undergoing a strategic transformation, including the divestment of its non-core Emulsifiers business, to focus on higher-growth, higher-margin opportunities.⁵¹ Its valuation is modest compared to F&F peers, with a P/E ratio of around 16x, reflecting its different business mix and historical margin profile.⁵³ Key risks include its capital-intensive nature and the successful scaling of its newer, high-growth platforms like algae-based omega-3s.

D. Archer Daniels Midland Company (ADM)

ADM is a global agricultural supply chain manager and processor, not a pure-play F&F company.⁵⁴ However, its Nutrition segment is a significant and growing player in the ingredients space, competing directly with the companies in this report. The Nutrition segment provides a wide array of ingredients, including plant-based proteins, natural flavors, flavor systems, and specialty ingredients for both human and animal nutrition.⁵⁵ In 2024, the Nutrition segment generated revenues of $7.35 billion but with a relatively low operating profit of $386 million, indicating significantly lower margins than its F&F peers.⁵⁵ A major recent development and significant risk factor is the internal and government investigation into accounting practices within the Nutrition segment, specifically related to intersegment sales.⁵⁵ This investigation led to the identification of a material weakness in internal controls and has created significant uncertainty and negative publicity for the company.⁵⁵ ADM’s valuation (consolidated P/E of ~19x ⁵⁷) must be viewed through a sum-of-the-parts lens, with the Nutrition segment’s value being weighed against the performance and risks of the much larger Ag Services & Oilseeds and Carbohydrate Solutions segments.

Company Profiles: Smaller Specialists

A. Robertet SA (RBT.PA)

Based in Grasse, France, Robertet is a family-controlled company renowned for its leadership in natural raw materials.⁵⁸ Its competitive advantage is its unique, vertically integrated “seed to scent” business model, which involves cultivating, harvesting, and processing its own aromatic plants. This provides unparalleled control over quality, supply, and transparency, which is highly valued in the current market environment.⁵⁸ The company operates across four divisions: Fragrances, Flavors, Raw Materials, and the smaller Health & Beauty segment.⁵⁹ Robertet delivered an excellent performance in 2024, with sales growing 12% to €807.6 million and net income rising 20% to €90.1 million.⁵⁹ Its valuation, with a P/E ratio around 20.5x, is robust for its size, reflecting its unique strategic positioning and strong growth in the naturals space.⁶⁰ The primary risk is its smaller scale and higher concentration in volatile natural raw materials compared to its larger, more diversified competitors.

B. Takasago International Corporation (4914.T)

Takasago is a major Japanese F&F company with a global presence across 28 countries and regions.⁶¹ It operates four business segments: Flavor, Fragrance, Aroma Ingredients, and Fine Chemicals.⁶² The company has a strong strategic focus on the Asian market, with Japan and the Asia-Pacific region accounting for a combined 54% of sales in the fiscal year ending March 2025.⁶² This provides direct exposure to the industry’s fastest-growing geographic region. For the fiscal year 2023, Takasago reported sales of JPY 195.9 billion (approx. USD 1.5 billion).⁶³ The company is advancing its “Vision 2040” strategy, which emphasizes sustainability under the slogan “Care for People, Respect the Environment”.⁶⁴ Its valuation is among the lowest in the peer group, with a P/E ratio of approximately 16.6x, potentially reflecting its lower profitability margins and geographic concentration.⁶⁵

Note on Private Companies

While this report focuses on publicly listed entities, it is important to acknowledge the presence of significant private competitors. Mane SA, a French family-owned company, is a major global player with reported sales of €1.7 billion in 2022.⁶⁶ Due to the absence of public financial filings, a detailed fundamental analysis is not possible, but its scale and capabilities place it as a key competitor to the public companies in this analysis.

Valuation Comparison & Framework

Valuation Comparison Matrix

A comparative valuation analysis is essential for contextualizing each company’s market standing. The following table provides a detailed comparison of key valuation multiples, historical averages, and other financial metrics across the peer group.

Table 2: Detailed Valuation Comparison Matrix

Company Ticker	Current P/E (TTM)	5-Yr Avg P/E	Current EV/EBITDA (TTM)	5-Yr Avg EV/EBITDA	Price/Sales (TTM)	Price/Book (TTM)	Dividend Yield (%)	FCF Yield (%)
GIVN.SW	36.4x	38.6x	21.1x	N/A	5.3x	9.0x	1.9%	3.2%
IFF	(23.4x)	39.5x	13.7x	18.2x	1.6x	1.3x	2.4%	3.0%
DSFIR.AS	23.8x	N/A	12.8x	N/A	1.7x	1.0x	3.0%	N/A
SY1.DE	22.9x	40.3x	15.6x	19.5x	2.2x	3.0x	1.5%	4.5%
SXT	35.9x	29.0x	14.9x	14.5x	3.2x	4.3x	1.5%	N/A
KRZ.L	22.0x	29.2x	14.6x	16.5x	2.0x	2.2x	1.3%	5.2%
CRBN.AS	16.4x	36.8x	10.1x	12.5x	0.9x	1.6x	3.5%	7.5%
ADM	19.4x	14.6x	8.5x	8.0x	0.3x	1.0x	3.7%	6.8%
RBT.PA	20.5x	25.8x	12.3x	16.0x	2.1x	3.1x	1.2%	1.3%
4914.T	16.6x	N/A	10.4x	N/A	0.6x	1.0x	3.9%	N/A
Note: Data as of latest available reporting periods and market data. Historical averages are approximate. FCF Yield is calculated as (LTM Free Cash Flow / Market Cap). ADM multiples are for the consolidated company.

Peer Group Analysis

The valuation matrix reveals distinct tiers within the F&F industry, driven by differences in perceived quality, growth prospects, and risk profiles.

• Premium Tier (Givaudan, Symrise): Givaudan stands alone with the highest valuation multiples, a testament to its consistent market leadership, superior profitability, and strong execution. Symrise also commands a premium valuation, reflecting its reliable growth and strong strategic positioning, though it trades at a discernible discount to Givaudan. The market awards these companies for their stability and high returns on capital.
• Turnaround/Value Tier (IFF, dsm-firmenich): Both IFF and dsm-firmenich trade at significant discounts to the premium tier. IFF’s negative P/E ratio highlights its recent GAAP losses from impairments, while its lower EV/EBITDA multiple reflects high debt and significant execution risk associated with its N&B integration. Similarly, dsm-firmenich’s valuation is tempered by the complexity and uncertainty of its large-scale merger and portfolio transformation. These stocks are valued based on the potential for future value creation from successful turnarounds, rather than on current performance.
• Specialist Tier (Robertet, Takasago): Robertet’s valuation is robust, reflecting its unique positioning as a pure-play on the high-growth natural ingredients trend. Takasago’s lower multiples are likely attributable to its geographic concentration in Asia and historically lower margins compared to its European peers.
• Diversified/Conglomerate Discount (Kerry, ADM, Corbion): These companies trade at lower multiples than the pure-play F&F leaders. This reflects a “conglomerate discount,” as the market values their F&F-related businesses as part of a broader, more complex portfolio. Their valuations are influenced by the performance and cyclicality of their other, non-F&F segments.

Risk-Adjusted Investment Framework & Concluding Remarks

Risk Assessment Summary

A comprehensive investment analysis requires a consolidated view of the key risks facing each company. The following matrix provides a qualitative assessment of the most salient risks, drawing from detailed disclosures in company filings.³⁵

Table 3: Consolidated Risk Matrix

Company Ticker	Raw Material & Supply Chain Risk	M&A / Integration Risk	Competitive & Margin Pressure	Geographic/ Political Risk	Governance/ Company-Specific Risk
GIVN.SW	Medium	Low	Low	Medium	Low
IFF	Medium	High	Medium	Medium	High
DSFIR.AS	Medium	High	Medium	Medium	High
SY1.DE	Medium	Low	Low	Medium	Low
SXT	Medium	Low	Medium	Medium	Low
KRZ.L	High	Medium	Medium	Medium	Medium
CRBN.AS	High	Low	High	Medium	Low
ADM	High	Medium	High	High	High
RBT.PA	High	Low	Medium	Medium	Medium
4914.T	Medium	Low	Medium	High	Low

Investment Ranking Framework

While not providing a direct recommendation, the following qualitative framework ranks the analyzed companies based on a composite of fundamental factors. This is intended to help align potential investments with specific strategic objectives.

• Market Leadership & Stability:

1. Givaudan: Unrivaled market leader with the most consistent track record.
2. Symrise: A strong and reliable #2, with excellent execution.
3. dsm-firmenich / IFF: Market leaders by scale, but currently lacking stability due to integrations.

• Margin Stability & Pricing Power:

1. Givaudan: Demonstrated ability to protect margins through pricing.
2. Symrise: Strong profitability and focus on margin expansion.
3. Robertet: Niche leadership in high-value naturals supports margins.

• Secular Growth Exposure (Naturals, Health & Wellness):

1. dsm-firmenich: Uniquely positioned at the intersection of F&F and Health/Nutrition.
2. Robertet: The purest play on the natural ingredients trend.
3. Givaudan / Symrise / IFF: All have strong and growing portfolios in this area.

• Balance Sheet Strength:

1. Givaudan / Symrise: Prudent leverage and strong cash flow generation.
2. dsm-firmenich: Moderate leverage post-merger.
3. IFF: High leverage is a primary constraint and risk factor.

• Valuation Attractiveness (Relative to Peers):

1. IFF: Deeply discounted, but reflects high risk.
2. dsm-firmenich: Appears reasonably valued if synergy targets are met.
3. Symrise: Trades at a premium, but offers a more reasonable entry point than Givaudan.

Thematic Investment Considerations

The analysis of the global F&F industry and its key players points to several distinct thematic considerations for investors:

• For Core, Defensive Growth Exposure: Investors seeking stable, long-term exposure to a defensive growth industry with high barriers to entry would naturally gravitate towards the established market leaders. Givaudan and Symrise represent the highest-quality options in this regard. They offer proven business models, consistent execution, strong balance sheets, and clear strategies. The primary trade-off is valuation, as the market already awards these companies with premium multiples.
• For Value and Turnaround Potential: The transformative mergers undertaken by IFF and dsm-firmenich have created a distinct value-oriented theme. Both companies trade at a significant discount to their high-quality peers, reflecting the substantial execution risks of their complex integrations and portfolio transformations. An investment in these companies is a bet on management’s ability to successfully navigate these challenges, de-lever their balance sheets, and unlock the latent value and synergy potential of their combined assets. The potential upside is considerable, but so are the risks of continued underperformance if these turnarounds falter.
• For Pure-Play Exposure to Secular Trends: For investors looking to make a more targeted bet on the powerful consumer shift towards natural ingredients, Robertet stands out. Its vertically integrated “seed to scent” model offers the most direct exposure to this theme. Similarly, for those seeking concentrated exposure to the high-growth Asian consumer market, Takasago offers a direct vehicle, albeit with the associated geographic and currency risks.
• For Broader Food Ingredient Exposure: Companies like Kerry Group, Corbion, and ADM’s Nutrition segment offer exposure to the F&F industry within a broader food and agricultural ingredients context. These companies may appeal to investors seeking a more diversified business model, though they typically come with lower overall margin profiles and exposure to different sets of risks compared to the pure-play F&F leaders. The company-specific issues at ADM, in particular, require careful consideration.

Works cited

1. Global Flavors And Fragrances Market Size & Outlook – Grand View Research, accessed August 4, 2025, https://www.grandviewresearch.com/horizon/outlook/flavors-and-fragrances-market-size/global
2. Global Flavors and Fragrances Market Size to Reach USD 50.61 – openPR.com, accessed August 4, 2025, https://www.openpr.com/news/4116367/global-flavors-and-fragrances-market-size-to-reach-usd-50-61
3. Flavors And Fragrances Market Size, Growth Drivers & Forecast, 2030 – Mordor Intelligence, accessed August 4, 2025, https://www.mordorintelligence.com/industry-reports/flavor-and-fragrance-market
4. Q1 2024 Raw Material Report – Flavorchem, accessed August 4, 2025, https://www.flavorchem.com/wp-content/uploads/2024/01/Q1-2024-Raw-Material-Report.pdf
5. Top 7 Chemical Industry Supply Chain Challenges in Trade Wars – CE Interim, accessed August 4, 2025, https://ceinterim.com/supply-chain-challenges-chemical-firms/
6. Natural Flavors And Fragrances Market Size Report, 2030 – Grand View Research, accessed August 4, 2025, https://www.grandviewresearch.com/industry-analysis/natural-flavors-fragrances-market-report
7. Flavors Market Size, Share & Growth | Industry Report, 2030 – Grand View Research, accessed August 4, 2025, https://www.grandviewresearch.com/industry-analysis/flavors-market
8. Food Flavor Market Size, Share & Trends Research Report 2025 – 2030, accessed August 4, 2025, https://www.mordorintelligence.com/industry-reports/food-flavor-market
9. Perfume Ingredient Market Projected to Reach $11.4 Billion by 2032, Says New Market Report, accessed August 4, 2025, https://www.perfumerflavorist.com/fragrance/ingredients/news/22945478/perfume-ingredient-market-projected-to-reach-114-billion-by-2032-says-new-market-report
10. Investor information – Givaudan, accessed August 4, 2025, https://www.givaudan.com/investors/investor-information
11. Investors | Givaudan, accessed August 4, 2025, https://www.givaudan.com/investors
12. 2023 Full year results | Givaudan, accessed August 4, 2025, https://www.givaudan.com/media/media-releases/2024/2023-full-year-results
13. Financial results | Givaudan, accessed August 4, 2025, https://www.givaudan.com/investors/financial-results
14. Financial targets | Givaudan, accessed August 4, 2025, https://www.givaudan.com/investors/financial-results/financial-targets
15. 2024 Full Year Results Presentation – Givaudan, accessed August 4, 2025, https://www.givaudan.com/files/giv-2024-fyr-presentation.pdf
16. Givaudan (GIVN.SW) – P/E ratio – Companies Market Cap, accessed August 4, 2025, https://companiesmarketcap.com/givaudan/pe-ratio/
17. Givaudan | GIVN – PE Price to Earnings – Trading Economics, accessed August 4, 2025, https://tradingeconomics.com/givn:vx:pe
18. $IFF International Flavors & Fragrances Q1 2025 Earnings Conference Call – YouTube, accessed August 4, 2025, https://www.youtube.com/watch?v=QGLxClP5ZII
19. IFF Reports Fourth Quarter and Full Year 2024 Results | International Flavors & Fragrances Inc., accessed August 4, 2025, https://ir.iff.com/news-releases/news-release-details/iff-reports-fourth-quarter-and-full-year-2024-results
20. International Flavors & Fragrances (IFF) Financials – Income Statement – Stock Analysis, accessed August 4, 2025, https://stockanalysis.com/stocks/iff/financials/
21. IFF Reports First Quarter 2025 Results | International Flavors & Fragrances Inc., accessed August 4, 2025, https://ir.iff.com/news-releases/news-release-details/iff-reports-first-quarter-2025-results
22. Press Releases | International Flavors & Fragrances Inc. – Investor Relations – IFF, accessed August 4, 2025, https://ir.iff.com/press-releases
23. IFF Investor Relations – International Flavors & Fragrances Inc – Alpha Spread, accessed August 4, 2025, https://www.alphaspread.com/security/nyse/iff/earnings-calls
24. IFF P/E Ratio: Current & Historical Analysis, accessed August 4, 2025, https://public.com/stocks/iff/pe-ratio
25. Ratios | International Flavors & Fragrances Inc. – Investor Relations – IFF, accessed August 4, 2025, https://ir.iff.com/financial-overview-ratios
26. DSM-Firmenich AG (0AC9) Company Information – Simply Wall St, accessed August 4, 2025, https://simplywall.st/stocks/gb/materials/lse-0ac9/dsm-firmenich-shares/information
27. dsm-firmenich’s journey – Investors, accessed August 4, 2025, https://investors.dsm-firmenich.com/en/investors/historical-information/dsm-firmenichs-journey.html
28. DSM-Firmenich H1 2025 Results – chemXplore, accessed August 4, 2025, https://chemxplore.com/news/dsm-firmenich-reports-h1-2025-results
29. dsm-firmenich reports H1 2025 results, accessed August 4, 2025, https://our-company.dsm-firmenich.com/en/our-company/news/press-releases/2025/dsm-firmenich-reports-h1-2025-results.html
30. Press Release: dsm-firmenich reports H1 2025 -2- – Finanznachrichten, accessed August 4, 2025, https://www.finanznachrichten.de/nachrichten-2025-07/66046699-press-release-dsm-firmenich-reports-h1-2025-2-015.htm
31. dsm-firmenich reports H1 2025 results – The Manila Times, accessed August 4, 2025, https://www.manilatimes.net/2025/07/31/tmt-newswire/globenewswire/dsm-firmenich-reports-h1-2025-results/2159470
32. DSM-Firmenich Stock Price | DSMFF Stock Quote, News, and History | Markets Insider, accessed August 4, 2025, https://markets.businessinsider.com/stocks/dsmff-stock
33. DSFIR Stock Price Quote | Morningstar, accessed August 4, 2025, https://www.morningstar.com/stocks/xams/dsfir/quote
34. The most important information for investors – Symrise, accessed August 4, 2025, https://www.symrise.com/investors/
35. Corporate Report 2024 Sharing Values – Symrise, accessed August 4, 2025, https://symrise.com/corporatereport/2024/home/Symrise_Unternehmensbericht_24_EN_interaktiv_geschuetzt.pdf
36. Corporate report 2024 | Konzernkennzahlen 2024 – Symrise, accessed August 4, 2025, https://symrise.com/corporatereport/2024/
37. Symrise Reports First Half 2025 Results, accessed August 4, 2025, https://www.symrise.com/newsroom/article/symrise-reports-first-half-2025-results/
38. Symrise AG (SYIEF) H1 2025 Earnings Call Transcript | Seeking Alpha, accessed August 4, 2025, https://seekingalpha.com/article/4806327-symrise-ag-syief-h1-2025-earnings-call-transcript
39. Symrise AG – PE Ratio – Wisesheets, accessed August 4, 2025, https://www.wisesheets.io/pe-ratio/SYIEY
40. SY1 Stock Price Quote | Morningstar, accessed August 4, 2025, https://www.morningstar.com/stocks/xfra/sy1/quote
41. Sensient Technologies Corporation – Investor Relations, accessed August 4, 2025, https://investor.sensient.com/overview/default.aspx
42. Sensient Technologies Corporation, accessed August 4, 2025, https://s202.q4cdn.com/397383768/files/doc_financials/2023/ar/2023-sxt-10-k.pdf
43. Sensient Technologies Corporation Reports Results for the Quarter Ended June 30, 2025, accessed August 4, 2025, https://investor.sensient.com/news-and-events/press-releases/news-details/2025/Sensient-Technologies-Corporation-Reports-Results-for-the-Quarter-Ended-June-30-2025/default.aspx
44. Sensient Technologies (SXT) P/E Ratio: Current & Historical Analysis, accessed August 4, 2025, https://public.com/stocks/sxt/pe-ratio
45. Sensient Technologies (SXT) – P/E ratio – Companies Market Cap, accessed August 4, 2025, https://companiesmarketcap.com/sensient-technologies/pe-ratio/
46. KRZ Investor Relations – Kerry Group PLC – Alpha Spread, accessed August 4, 2025, https://www.alphaspread.com/security/iseq/krz/investor-relations
47. Kerry Group (KRZ) Investor Relations Material – Quartr, accessed August 4, 2025, https://quartr.com/companies/kerry-group-plc_15476
48. Kerry Group Annual Report 2024 – RNS Submit, accessed August 4, 2025, http://www.rns-pdf.londonstockexchange.com/rns/3101B_1-2025-3-19.pdf
49. Kerry Group (LSE:KYGA) Stock Valuation, Peer Comparison & Price Targets – Simply Wall St, accessed August 4, 2025, https://simplywall.st/stocks/gb/food-beverage-tobacco/lse-kyga/kerry-group-shares/valuation
50. Corbion (CRBN) Investor Relations Material – Quartr, accessed August 4, 2025, https://quartr.com/companies/corbion-n-v_14657
51. Corbion Annual Report 2024 – Euronext Markets, accessed August 4, 2025, https://live.euronext.com/sites/default/files/esg_document_files/2025-04/004396_Corbion_annual_report_2024_2025-04-04_14%3A09.pdf
52. Corbion announces strong full-year results with sales growth, +25% Adjusted EBITDA improvement, and strong FCF, accessed August 4, 2025, https://www.corbion.com/-/media/corbion/files/quarterly/2024/2025-02-27_corbion_press-release-4q-fy-2024.pdf
53. Corbion N.V. (XFRA:CSU) P/E Ratio – Investing.com, accessed August 4, 2025, https://www.investing.com/pro/XFRA:CSU/explorer/pe_ltm
54. ADM – Investor Relations, accessed August 4, 2025, https://www.investors.adm.com/
55. FORM 10-K, accessed August 4, 2025, https://s1.q4cdn.com/365366812/files/doc_financials/2024/q4/3099d36c-efca-4ad4-8b3b-6aab2ec12df7.pdf
56. adm-20241231 – SEC.gov, accessed August 4, 2025, https://www.sec.gov/Archives/edgar/data/7084/000000708425000011/adm-20241231.htm
57. ADM – Archer-Daniels-Midland PE ratio, current and historical analysis – FullRatio, accessed August 4, 2025, https://fullratio.com/stocks/nyse-adm/pe-ratio
58. RBT Investor Relations – Robertet SA – Alpha Spread, accessed August 4, 2025, https://www.alphaspread.com/security/par/rbt/investor-relations
59. ANNUAL REPORT – Robertet, accessed August 4, 2025, https://www.robertet.com/wp-content/uploads/2025/04/Robertet_RA-2024_Complet-Pages-EN_BD.pdf
60. Robertet (CBE.PA) – P/E ratio – Companies Market Cap, accessed August 4, 2025, https://companiesmarketcap.com/robertet/pe-ratio/
61. Takasago International Corporation, accessed August 4, 2025, https://www.takasago.com/en
62. Takasago in a Nutshell, accessed August 4, 2025, https://www.takasago.com/en/5minutes
63. Sustainability Report 2024, accessed August 4, 2025, https://assets.takasago.com/prod/default/s3fs-public/2024-08/TAKASAGO_Sustainability%20Report%202024_0383014162408.pdf
64. Top Message | Takasago International Corporation, accessed August 4, 2025, https://www.takasago.com/en/ir/message.html
65. Takasago International Corporation (4914.T) – P/E ratio, accessed August 4, 2025, https://companiesmarketcap.com/takasago-international-corporation/pe-ratio/
66. Mane SA – Wikipedia, accessed August 4, 2025, https://en.wikipedia.org/wiki/Mane_SA
67. iff-20231231 – SEC.gov, accessed August 4, 2025, https://www.sec.gov/Archives/edgar/data/51253/000005125324000006/iff-20231231.htm